Literature DB >> 9189043

A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes.

T Gómez-Isla1, W Wasco, W P Pettingell, S Gurubhagavatula, S D Schmidt, P D Jondro, M McNamara, L A Rodes, T DiBlasi, W B Growdon, P Seubert, D Schenk, J H Growdon, B T Hyman, R E Tanzi.   

Abstract

The prevalence of known mutations in presenilin genes (PS1 and PS2) causing early-onset familial Alzheimer's disease (FAD) was assessed in a population of 98 singleton early-onset AD cases, 29 early-onset FAD cases, and 15 late-onset FAD cases. None of the cases tested positive for the eight mutations initially reported, and none of these mutations were observed in 60 age-matched controls. A novel mutation (R269H) in PS1 was found in a single case of early-onset AD but not in any other AD or control case. Thus, the PS mutations tested are quite rare in early-onset AD. Amyloid beta protein (A beta) deposition was investigated in the temporal cortex of the R269H mutation case using end-specific monoclonal antibodies to detect the presence of A beta x-40 and A beta x-42 subspecies. Stereologically unbiased tangle and neuropil thread counts were obtained from the same region. R269H PS1 mutation was associated with early age of dementia onset, higher amounts of total A beta and A beta x-42, and increased neuronal cytoskeletal changes. Thus, if the changes observed on this case prove to be typical of PS1 mutations, PS1 mutations may impact both amyloid deposition and neurofibrillary pathology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9189043     DOI: 10.1002/ana.410410618

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  18 in total

1.  Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.

Authors:  D M Mann; S M Pickering-Brown; A Takeuchi; T Iwatsubo
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease.

Authors:  Yakeel T Quiroz; Andrew E Budson; Kim Celone; Adriana Ruiz; Randall Newmark; Gabriel Castrillón; Francisco Lopera; Chantal E Stern
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

3.  Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains.

Authors:  Masahiro Ono; Shun Hayashi; Kenji Matsumura; Hiroyuki Kimura; Yoko Okamoto; Masafumi Ihara; Ryosuke Takahashi; Hiroshi Mori; Hideo Saji
Journal:  ACS Chem Neurosci       Date:  2011-03-21       Impact factor: 4.418

Review 4.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

5.  Cerebral microbleeds in familial Alzheimer's disease.

Authors:  Natalie S Ryan; António J Bastos-Leite; Jonathan D Rohrer; David J Werring; Nick C Fox; Martin N Rossor; Jonathan M Schott
Journal:  Brain       Date:  2011-06-17       Impact factor: 13.501

6.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum.

Authors:  D Campion; C Dumanchin; D Hannequin; B Dubois; S Belliard; M Puel; C Thomas-Anterion; A Michon; C Martin; F Charbonnier; G Raux; A Camuzat; C Penet; V Mesnage; M Martinez; F Clerget-Darpoux; A Brice; T Frebourg
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

7.  Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease.

Authors:  Aditi Joshi; John M Ringman; Albert S Lee; Kevin O Juarez; Mario F Mendez
Journal:  J Neurol       Date:  2012-03-30       Impact factor: 4.849

8.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype.

Authors:  James B Leverenz; Mark A Fishel; Elaine R Peskind; Thomas J Montine; David Nochlin; Ellen Steinbart; Murray A Raskind; Gerard D Schellenberg; Thomas D Bird; Debby Tsuang
Journal:  Arch Neurol       Date:  2006-03

9.  Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.

Authors:  A Takashima; M Murayama; O Murayama; T Kohno; T Honda; K Yasutake; N Nihonmatsu; M Mercken; H Yamaguchi; S Sugihara; B Wolozin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Widespread white matter and conduction defects in PSEN1-related spastic paraparesis.

Authors:  Steffan K Soosman; Nelly Joseph-Mathurin; Meredith N Braskie; Yvette M Bordelon; David Wharton; Maria Casado; Giovanni Coppola; Holly McCallum; Marc Nuwer; Pedro Coutin-Churchman; Liana G Apostolova; Tammie Benzinger; John M Ringman
Journal:  Neurobiol Aging       Date:  2016-08-08       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.